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Abstract
STK295900, a small synthetic molecule belonging to a class of symmetric bibenzimidazoles, exhibits antiproliferative activity
against various human cancer cell lines from different origins. Examining the effect of STK295900 in HeLa cells indicates that
it induces G2 phase arrest without invoking DNA damage. Further analysis shows that STK295900 inhibits DNA relaxation
that is mediated by topoisomerase 1 (Top 1) and topoisomerase 2 (Top 2) in vitro. In addition, STK295900 also exhibits
protective effect against DNA damage induced by camptothecin. However, STK295900 does not affect etoposide-induced
DNA damage. Moreover, STK295900 preferentially exerts cytotoxic effect on cancer cell lines while camptothecin, etoposide,
and Hoechst 33342 affected both cancer and normal cells. Therefore, STK295900 has a potential to be developed as an
anticancer chemotherapeutic agent.
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Introduction
Cancer is a multi-step process resulting from acquired genetic
and epigenetic alterations that abrogate normal control of cellular
functions and eventually lead to uncontrollable cell growth and
proliferation [1,2]. In recent years, the advances in understanding
the molecular basis of cancer have led to a significant improve-
ment of diagnostics and therapeutics for a better management of
diseases. However, a number of chemotherapeutic agents that
exert chemotherapeutic action through their ability to inhibit
nuclear DNA topoisomerases (Tops) have been the mainstay of
cancer treatment for many decades [3].
Tops are evolutionally conserved nuclear enzymes, which are
essential for DNA metabolism where they are involved in
generating the necessary topological state of DNA during
replication, transcription, recombination, and chromatin remod-
eling [4,5]. Tops act by introducing a sequential breakage and
rejoining of one DNA strand (Top 1) or both DNA strands (Top 2)
allowing DNA to be transformed between topological isoforms.
Therefore, these enzymes have been identified as important
targets for cytotoxic drugs and their inhibitors are widely used for
decades in cancer chemotherapy.
The Top inhibitors can be classified into two classes according
to their mechanism of action: Top poisons and catalytic inhibitors
[3,6,7]. Top poisons, such as camptothecin and etoposide are able
to stabilize the covalent complexes between the enzyme and DNA,
termed cleavable complex, and prevent the rejoining step of the
reaction thereby resulting in accumulation of DNA strand break.
Consequently, tumor cell death is triggered by the substantial
DNA damage evoked by Top poisons [8,9]. On the other hand,
the catalytic inhibitors act on any of the other steps in the catalytic
cycle by preventing the binding between Top and DNA
(aclarubicin) or interfering with the binding or release of ATP
(novobiocin, ICRF-193), resulting in activating the decatenation
checkpoint [7,10,11].
We report here a symmetric bibenzimidazole derivative,
STK295900, as a Top catalytic inhibitor. STK295900 efficiently
inhibited the growth of various cancer cell lines such as HeLa,
MCF7, HepG2, and HL-60. In addition, cells treated with
STK295900 were arrested in G2 phase without activation of DNA
damage checkpoint. These findings may therefore suggest a
potential development of symmetric bibenzimidazole as a chemo-
therapeutic agent.
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Materials and Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM), RPMI 1640,
and DMEM/F12 were purchased from HyClone (Logan, UT).
Fetal bovine serum (FBS) was purchased from Invitrogen (San
Diego, CA). ICRF-193 was obtained from Enzo Life science
(Farmingdale, NY). Camptothecin, etoposide, nocodazole, and b-
actin antibody were purchased from Sigma-Aldrich (St. Louis,
MO). Phospho-Cdk1 (T14), phospho-Cdk1 (Y15), phospho-Cdk1
(T161), Cdk1, cyclin B1, phospho-ATM (S1981), ATM, phospho-
ATR (S428), ATR, phospho-Chk1 (S345), Chk1, phospho-Chk2
(T68), Chk2, phospho-Histone H3 (S10), Histone H3, and c-
H2A.X (S139) antibodies were purchased from Cell Signaling
Technology (Denvers, MA). Cyclin A, Wee1, Cdc25C, p53, p21,
and GAPDH antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA).
Cell Culture and Cell Growth Inhibition Assay
Human epitheloid cervical carcinoma HeLa cells, human breast
adenocarcinoma MCF7 and MDA-MB-231cells, human hepato-
cellular carcinoma HepG2 cells, human colon adenocarcinoma
HT-29 cells, and human colorectal carcinoma HCT-116 cells
were purchased from ATCCH and maintained in DMEM
medium. Human prostate carcinoma PC-3 cells (purchased from
ATCCH), human gastric carcinoma SNU-484 and SNU-601(ob-
tained from Korean Cell Line Bank (KCLB)), human leukemia K-
562 and HL-60 cells (purchased from ATCCH), immortalized
human prostate epithelial 267B1cells [12], and immortalized
human embryonic lung fibroblast MRC5CV1 cells [13] were
maintained in RPMI 1640 medium whereas immortalized retinal
pigment epithelial hTERT RPE-1 cells (purchased from ATCCH)
were maintained in DMEM/F12 medium. All cell lines were
cultured in media supplemented with 10% fetal bovine serum,
100 U/ml penicillin, and 100 mg/ml streptomycin at 37uC in a
5% CO2 incubator.
Cells were seeded at the appropriate amount (1–26103 cells) in
triplicate in 96-well plates for 24 h and then treated with various
concentrations of STK295900. Cell growth was determined by
using EZ-CyTox cell viability assay kit (Daeil Lab. Service, Seoul,
Korea). Ten microliters of WST solution were added to the
treated cells at 24, 48, 72, and 96 h. Cells were further incubated
at 37uC for 2 h and the absorbance was measured at 450 nm.
Flow Cytometric Analysis
For cell cycle analysis, HeLa cells were harvested following
compound treatment for 24 h and stained with propidium iodide
(PI) according to the instruction of Cycle Test Plus DNA Reagent
kit from BD Biosciences (San Jose, CA). Flow cytometric analysis
was performed using a FACSCalibur instrument (Becton Dick-
inson, San Jose, CA).
Supercoiled DNA Relaxation Assay for Topoisomerase 1
The relaxation assay for topoisomerase 1 was performed using
purified calf thymus topoisomerase 1 and pBR322 plasmid DNA
(Takara Bio, Shiga, Japan). In brief, 0.25 mg of pBR322 DNA was
incubated with 1 unit of topoisomerase 1 in 20 ml reaction
containing 35 mM Tris-HCl pH 8.0, 72 mM KCl, 5 mM MgCl2,
5 mM DTT, 5 mM spermidine, and 0.1% BSA. The mixture was
incubated for 30 min at 37uC in the presence or absence of
STK295900 and camptothecin. The reaction was terminated by
addition of 2 ml 10% SDS and then treated with 50 mg/ml
proteinase K for 30 min at 37uC to digest the protein. Samples
were resolved by electrophoresis on 1% agarose gel. After gel
electrophoresis, the gel was stained with ethidium bromide and
DNA bands were visualized by UV light and photographed using
Gel Doc XR (Bio-Rad, Hercules, CA).
Supercoiled DNA Relaxation Assay for Topoisomerase 2a
The relaxation assay for topoisomerase 2a was performed in
20 ml reaction mixture containing 0.25 mg of plasmid pBR322
DNA in DNA topoisomerase 2 buffer (50 mM Tris-HCl pH 8.0,
150 mM NaCl, 10 mM MgCl2, 2 mM ATP, and 0.5 mM DTT)
and 1 unit of human topoisomerase 2a in the absence or presence
of STK295900, etoposide, or ICRF-193 for 30 min at 37uC. After
incubation, the reaction was terminated by addition of 2 ml of 10%
SDS. The reaction mixtures were treated with 50 mg/ml
proteinase K for 30 min at 37uC and then DNA was extracted
with CIA (chloroform:isoamyl alcohol, 24:1). Samples were
resolved by electrophoresis on a 1% agarose gel. After staining
the electrophoresed gel with ethidium bromide, DNA bands were
visualized by UV light and photographed on Gel Doc XR.
Immunofluorescence Cell Staining
For phospho-Histone H2A.X (S139) staining, HeLa cells were
cultured in black 96-well plate for 24 h. Cells were then treated
with STK295900, ICRF-193, etoposide, and camptothecin for
another 24 h. The treated cells were fixed with 3.7% formalde-
hyde for 20 min, washed once with PBS, and permeabilized by
0.2% Triton X-100 in PBS for 5 min at room temperature. After
blocking the samples with 5% BSA in PBS for 30 min at room
temperature, the cells were incubated sequentially with the
phospho-Histone H2A.X (S139) antibody (1:50 dilution in
0.02% Triton X-100 and 0.1% BSA in PBS) for 90 min at 37uC
and then with Alexa-conjugated secondary antibody (1:200
dilution in PBS containing 0.1% BSA) for 60 min at 37uC.
DNA of ICRF-193-, etoposide-, and camptothecin-treated cells
was stained with 0.5 mg/ml Hoechst 33342 in PBS. Images were
analyzed on a fluorescence microscope (Nikon Instruments Inc.,
Melville, NY).
Immunoblot
Cells were lysed with cold RIPA buffer (50 mM Tris-HCl
pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS) containing freshly added protease inhibitor, phospha-
tase inhibitor (SIGMA), 1 mM DTT, and 1 mM Na3VO4 on ice
for 1 h. Whole cell lysates were centrifuged at 15,000 rpm for
20 min and then the supernatant was transferred into a new tube.
An appropriate amount of cell lysate was subjected to SDS-PAGE.
Then the resolved proteins were transferred onto a PVDF
membrane (Bio-Rad) for immunoblot analyses with specific
antibodies. The proteins were detected using chemiluminescence
solution (Thermo Scientific, Rockford, IL).
Results
Effect of STK295900 on Various Human Cancer Cells
In our effort to identify new antiproliferative compounds from
small molecule library, we found a symmetric bibenzimidazole
derivative STK295900 (4,49-(3H,39H-5,59-bibenzimidazole-2,29-
diyl)dianiline) (Fig. 1A) that strongly inhibited the growth of
various cancer cell lines. As shown in Fig. 1B, STK295900
efficiently suppressed the growth of HeLa, MCF7, HT-29, and
HL-60 cells in a dose-dependent manner with IC50 values 0.52,
0.06, 0.27, and 0.50 mM, respectively (Table 1). Furthermore,
STK295900 also inhibited the growth of the other cancer cell lines
including MDA-MB-231, HepG2, HCT-116, K-562, PC-3, SNU-
484, and SNU-601 cells, with IC50 ranging from 0.51–2.83 mM
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Figure 1. Effects of STK295900 on proliferation of various human cancer cell lines. (A) Chemical structure of STK295900. (B) Inhibitory
effects of STK295900 on the proliferation of variety of cancer cell lines. Cells were seeded at 1226103 cells in 96 well plates and treated with various
concentrations of STK295900 for 4 days. Cell growth was determined by MTT assay. Data were fitted with dose-response curve using Graphpad Prism
software. Values represent the mean 6 SD from a representative triplicate experiment.
doi:10.1371/journal.pone.0053908.g001
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(Table 1). These results indicate that STK295900 exhibits
antiproliferative effect against a variety of cancer cell types.
Moreover, we also compared the cytotoxic effects of
STK295900, Top 1 inhibitors (camptothecin and Hoechst
33342), and Top 2 inhibitor (Etoposide) in various cell lines
including cancer (HeLa, MCF7, HepG2, and HT-29) and non-
cancerous cell lines (hTERT RPE-1, 267B1, and MRC5CV1).
Camptothecin exhibited strong cytotoxicity towards all cell lines
tested with IC50 less than 30 nM while etoposide also showed high
cytotoxicity against those cells except MCF7 and HT-29 (IC50
13.21 and 10.26 mM, respectively) (Table 2). The effect of Hoechst
33342 was diverse and non-selective against cancer cells (Table 2).
In contrast, STK295900 exhibited selective toxicity against cancer
cells (IC50s 0.64, 0.04, 0.14, and 0.21 mM in HeLa, MCF7,
HepG2, and HT-29, respectively) when compared to non-cancer
cells (IC50s 3.43, 1.61, and 0.95 mM in hTERT RPE-1, 267B1,
and MCR5CV1, respectively) (Table 2).
STK295900 Induces G2 Phase Arrest
Given its strong growth inhibitory effect on various cancer cell
types, STK295900 was examined to determine its effect on cell
cycle distribution using flow cytometry analysis. As shown in
Fig. 2A, around 25% of HeLa control cells were in G2/M phase
with 4N DNA content. Treatment with STK295900 at 0.5, 1, and
5 mM for 24 h resulted in increased G2/M population to about
35%, 55%, and 65%, respectively. This result suggested that
STK295900 could induce G2/M phase arrest. We then analyzed
whether the increasing G2/M population in Fig. 2A is indeed G2
or M phase by determining the mitotic index and investigating the
cell cycle regulatory proteins. To determine mitotic index, the
treated cells were stained with Hoechst 33342 and then mitotic
cells were counted. However, we observed no significant change in
mitotic index after treatment with various concentrations of
STK295900 (Fig. 2B) suggesting that STK295900 might cause cell
cycle arrest at G2 phase.
To confirm the G2 arrest effect of STK295900, we then
investigated cell cycle related proteins including cyclin A, cyclin
B1, and Histone H3 phosphorylation. Camptothecin, etoposide,
and nocodazole were used as controls for G2 and M phases.
Camptothecin and etoposide inhibit Top 1 and Top 2 activities,
respectively, thereby inducing G2 arrest whereas nocodazole
causes microtubule depolymerization resulting in mitotic arrest
[14–16]. It has been well established that cyclin A and cyclin B1
levels are altered through the cell cycle [17]. The level of cyclin A
was increased during S and G2 phases but declined in mitosis
while cyclin B1 was made at S phase and reached the maximum
level at M phase. Treatment of HeLa cells with STK295900,
camptothecin, and etoposide for 24 h led to accumulations of
cyclin A and cyclin B1 (Fig. 2C). In contrast, nocodazole treatment
resulted in mitotic arrest with high level of cyclin B1 and
undetectable level of cyclin A (Fig. 2C). Furthermore, Histone H3
phosphorylation at S10, a well-known mitotic marker [18], was
detected only in cells treated with nocodazole but not with
STK295900, camptothecin, or etoposide. Taken together, these
data indicated that STK295900 induced G2 arrest.
Effect of STK295900 on Cdk1 Phosphorylation
In addition to cyclin B1 binding, Cdk1 activity also requires
phosphorylation at T161 in its activation loop. Nonetheless, the
activity of Cdk1 is kept in check by inhibitory phosphorylations at
Y15 and T14 by Wee1 and Myt1, respectively [19,20]. We then
investigated the phosphorylation state of Cdk1 at 24 h after
treatment with STK295900, camptothecin, etoposide, and
nocodazole. Phosphorylation of Cdk1 at T161 was strongly
enhanced in cells treated with camptothecin, etoposide, and
nocodazole (Fig. 3A). In contrast, the inhibitory phosphorylation
(T14 and Y15) could not be detected in nocodazole-treated cells
but was abundance in camptothecin- and etoposide-treated cells
(Fig. 3A). STK295900 treatment displayed dose-dependent
increase in Cdk1 phosphorylations at T14, Y15, and T161, but
the signal intensities were somewhat weaker than in cells treated
with camptothecin and etoposide (Fig. 3A). However, treatment of
STK295900 in HeLa cells also caused accumulation of Cdk1
whose level was comparable to the increased in its phosphorylation
level.
Moreover, we also observed no change in Wee1 and Cdc25C
levels in STK295900-treated cells while camptothecin and
etoposide treatments caused reduction of Cdc25C (Fig. 3A).
Unlike STK295900, nocodazole treatment resulted in undetect-
Table 1. Inhibitory effect of STK295900 on proliferation of
various cancer cell lines.
Tumor Cell Line IC50 (mM)
Cervical carcinoma HeLa 0.52
Breast adenocarcinoma MCF7 0.06
MDA-MB-231 0.51
Hepatocellular carcinomar HepG2 0.17




Prostate carcinoma PC-3 2.72
Gastric carcinoma SNU-484 1.21
SNU-601 2.21
Cells were seeded at 1226103 cells in 96 well plates and treated with various
concentrations of STK295900. Cell growth was determined by MTT assay for up
to 4 days. All experiments were done in triplicates and IC50 was calculated from
log-dose-response curves.
doi:10.1371/journal.pone.0053908.t001
Table 2. Comparison of STK295900 with camptothecin,
etoposide, and Hoechst 33342 for its effect on the
proliferation of various cancer and non-cancer cell lines.
IC50 (mM)
Cell Line STK295900 Camptothecin Etoposide
Hoechst
33342
HeLa 0.64 0.02 0.30 4.56
MCF7 0.04 0.03 13.21 0.20
HepG2 0.14 0.02 0.84 0.22
HT-29 0.21 0.03 10.26 0.65
hTERT RPE-1 3.43 ,0.01 0.45 1.01
267B1 1.61 ,0.01 0.39 0.84
MRC5CV1 0.95 0.02 1.29 0.35
Cells were seeded at 1226103 cells in 96 well plates and treated with various
concentrations of STK295900, camptothecin, etoposide, or Hoechst 33342. Cell
growth was determined by MTT assay for up to 4 days. All experiments were
done at least in triplicates, and IC50 was calculated from dose-response curves.
doi:10.1371/journal.pone.0053908.t002
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Figure 2. STK295900 induces G2 phase arrest in HeLa cells. (A) Flow cytometric analysis for cell cycle distribution. HeLa cells were treated with
the indicated concentrations of STK295900 for 24 h. Treated cells were then stained with propidium iodide (PI) and processed for cell cycle analysis.
The bar graph represents the mean percentage of each cell cycle phase 6 SD from three independent experiments. * = p,0.05 versus the respective
G1, S, or G2/M phase of DMSO-treated cells. (B) Mitotic index of STK295900. HeLa cells were treated with the indicated concentrations of STK295900
for 24 h. Cells were then stained with Hoechst 33342 and mitotic cells were counted. The bar graph shows mean 6 SD from the representative of
triplicate experiments. (C) Cell cycle related proteins expression. HeLa cells were treated with DMSO control, STK295900 (STK) 1 or 5 mM,
camptothecin (CPT) 10 mM, etoposide (ETO) 10 mM, or nocodazole (NOC) 200 ng/ml for 24 h. Treated cells were lysed and subjected to immunoblot
analyses with antibodies against cyclin A, cyclin B1, phospho-Histone H3 (S10), and Histone H3. b-actin was used as a loading control.
doi:10.1371/journal.pone.0053908.g002
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able levels of Wee1 but activation of Cdc25C as indicated by
retarded migration on SDS-PAGE (Fig. 2C), reflecting its
hyperphosphorylation at G2/M transition [21]. Taken together,
these results suggested that STK295900-induced G2 arrest is
unlikely due to suppression of Cdk1 activity by inhibitory
phosphorylations at T14 and Y15.
STK295900 does not Activate DNA Damage Checkpoint
Many widely used chemotherapeutic agents cause DNA
damage by targeting DNA or enzymes that regulate DNA
topology resulting in DNA damage induced G2 arrest [14,22].
DNA damage leads to activation of ATM/ATR signaling pathway
[23]. Therefore we investigated whether the G2 arrest induced by
Figure 3. STK295900 does not activate DNA damage checkpoint. (A) G2/M transition regulated proteins expression. HeLa cells were treated
with STK295900 1 or 5 mM, Camptothecin 10 mM, etoposide 10 mM, or nocodazole 200 ng/ml. After 24 h incubation, cell lysates were prepared for
immunoblot analyses with antibodies against phospho-Cdk1 (T161), phospho-Cdk1 (T14), phospho-Cdk1 (Y15), Cdk1, Wee1, and Cdc25C. GAPDH was
used as a loading control. (B) DNA damage-checkpoint related proteins. The same lysates used in (A) were subjected to immunoblot analyses with
antibodies against phospho-ATM (S1981), ATM, phospho-ATR (S428), ATR, phospho-Chk1 (S345), Chk1, phospho-Chk2 (T68), Chk2, p53, and p21. b-
actin was used as a loading control. (C) Immunofluorescence staining for c-H2A.X. HeLa cells were treated with 1, 5, or 10 mM of STK295900 or 10 mM
of ICRF-193, etoposide, and camptothecin for 24 h. Treated cells were then fixed and stained with anti-c-H2A.X (middle panel). DNA from ICRF-193-,
etoposide-, and camptothecin-treated cells was stained with Hoechst 33342 (bottom panel). Images were analyzed on a fluorescence microscope.
doi:10.1371/journal.pone.0053908.g003
STK295900 Inhibits Tops and Induces G2 Arrest
PLOS ONE | www.plosone.org 6 January 2013 | Volume 8 | Issue 1 | e53908
STK295900 is due to DNA damage checkpoint activation by
analyzing the phosphorylation-dependent activation of ATM
(S1981), ATR (S428), Chk1 (S345), and Chk2 (T68). As shown
in Fig. 3B, treatment with camptothecin and etoposide resulted in
activation of ATM, Chk1, and Chk2 as judged by the increased
phosphorylation. However, no increase in phosphorylations of
ATM, ATR, Chk1, and Chk1 were observed in STK295900-
treated cells (Fig. 3B). In addition, while p53 and p21 levels were
only weakly upregulated in etoposide-treated cells, they were
significantly increased in camptothecin-treated sample (Fig. 3B).
Interestingly, however, STK295900 did not induce upregulation
of p53 but marginally affected p21 level (Fig. 3B).
To confirm that STK295900 did not induce DNA strand break,
we then measured Histone H2A.X phosphorylation at S139 (c-
H2A.X), a hallmark of DNA strand break in cells [24]. HeLa cells
were treated with 1, 5, or 10 mM of STK295900. Top poisons
(etoposide and camptothecin) and Top catalytic inhibitor (ICRF-
193) were used as controls. After treatment for 24 h, cells were
subjected to immunostaining with anti-c-H2A.X. As shown in
Fig. 3C, STK295900, like ICRF-193, did not induce c-H2A.X
signal while Top poisons etoposide and camptothecin strongly
induced it (Fig. 3C). Taken together, these data indicated that G2
arrest induced by STK295900 was irrelevant to DNA damage.
Furthermore, we also observed that STK295900 could stain DNA
and be also excited by ultraviolet light to emit blue fluorescence
similar to Hoechst 33342 (Fig. 3C) suggesting that STK295900
bind to DNA and therefore might exert its effect through this
mechanism.
STK295900 Inhibits Tops Activities
Many DNA-binding compounds exhibit their major pharma-
cological effect through interference with the activity of Tops [25].
Therefore, we firstly investigated the effect of STK295900 on Top
1-mediated DNA relaxation. Top cleaves supercoiled DNA and
thereby converts it to less-supercoiled form [4]. DNA relaxation
assay was performed using purified Top 1 in the presence of
various concentrations of STK295900. As shown in Fig. 4A,
STK295900 as well as camptothecin (Top 1 poison) inhibited
DNA relaxation activity of Top 1 in a dose-dependent manner as
judged by a decrease in relaxed DNA and an increase in nicked-
open-circular DNA due to stabilization of the cleavage complex.
However, supercoiled DNA could be observed in samples treated
with high concentrations of STK295900 (50 and 100 mM), but not
with camptothecin, indicating that STK295900 at high concen-
tration may also inhibit Top 1 catalytic activity in vitro.
In addition, we also analyzed the effect of STK295900 on Top
2a-mediated DNA relaxation. Etoposide (Top 2 poison) and
ICRF-193 (Top 2 catalytic inhibitor) were used as controls
according to their activities. Fig. 4B demonstrated that etoposide
inhibited Top 2a activity by reducing the relaxed DNA and
increasing nicked-open-circular DNA. In contrast, STK295900
also inhibited Top 2a-mediated DNA relaxation in a manner
similar to ICRF-193 resulting in accumulation of supercoiled
DNA (Fig. 4B). Taken together, these data indicated that
STK295900 inhibits both Top 1 and Top 2 activities in vitro.
However, as shown in Fig. 3C, STK295900 did not induce
DNA strand break associated c-H2A.X signal, suggesting that it
functions as Top catalytic inhibitor. To determine antagonistic
effect of STK295900 on Top poison-mediated DNA damage,
HeLa cells were pretreated with DMSO or STK295900 for
30 min and then incubated with 10 mM or 30 mM of camptothe-
cin or etoposide for 1 h. The lysates were subjected to immunoblot
analyses with c-H2A.X antibody. In control cells, camptothecin
and etoposide treatment strongly induced c-H2A.X (Figs. 4C &
4D). STK295900 pretreatment dramatically reduced camptothe-
cin-induced c-H2A.X (Fig. 4C). Interestingly, however,
STK295900 up to 50 mM, could not prevent etoposide-induced
c-H2A.X (Fig. 4D). These results indicated that STK295900
antagonizes Top 1 poison-mediated DNA damage.
Discussion
In the search for new chemotherapeutic agents from the small
molecule library, we identified STK295900 (Fig. 1A) that
exhibited efficient antiproliferative activity against various cancer
cell lines of different origin, especially MCF7 and HepG2 (Fig. 1B
and Table 1). Furthermore, analyzing the effect of STK295900 on
HeLa cells demonstrated that it induced G2 cell cycle arrest (Fig. 2).
This is due to STK295900-induced accumulation of 4N DNA
content with no significant change in mitotic index (Figs. 2A and
2B). In addition, STK295900-induced G2 arrest was confirmed by
investigating the cell cycle regulatory proteins. Progression
through the eukaryotic cell cycle is driven in part by a subfamily
of Cdks whose activities are modulated by forming bipartite
complexes with different cyclins [26]. Levels of cyclins oscillate
throughout the cell cycle whereas Cdk protein levels remain stable
[27,28]. Therefore, the activity of Cdks is regulated by the
presence of different cyclins. In mitotic cells, cyclin B1 level was
relatively high whereas cyclin A was undetectable (Fig. 2C). In
contrast, STK295900 showed similar effect as camptothecin and
etoposide did on cyclin A and cyclin B1 accumulation without
induction of Histone H3 phosphorylation at S10 (Fig. 2C), which
is crucial for chromosome condensation and cell-cycle progression
during mitosis [18,29].
STK295900 belongs to a class of symmetric bibenzimidazole
group. Compounds containing benzimidazole ring have been used
extensively for pharmacological purposes such as antimicrobial
and anticancer agents [30]. Several asymmetric, head-to-tail
bibenzimidazole derivatives, such as Hoechst 33258 and Hoechst
33342, exhibited antitumor activity by binding to minor groove of
DNA at three consecutive A:T base pairs, leading to the inhibition
of Top 1 activity [31,32]. In addition, the symmetric bibenzimi-
dazole derivatives, containing two groups of benzimidazole linked
in head-to-head fashion, have been reported that they bind DNA
minor groove with extending the binding site to four A:T base
pairs and exhibit antitumor activity [33]. However, there is no
report on the mechanism of action for their antitumor activity.
Here, we showed that STK295900 exerted its activity by
interfering with Top 1 and Top 2 activities (Fig. 4). In support
of this notion, STK295900 was recently reported as a potent anti-
staphylococcal agent by targeting DNA gyrase [34]. The results
from DNA relaxation assay suggested that STK295900 stabilizes
the DNA-Top 1 cleavable complex, a characteristic of Top
poisons (Fig. 4A), but it also inhibited Top 2 catalytic activity
(Fig. 4B).
Generally, Top poisons causes DNA strand break and
consequently triggers G2 arrest via activation of ATM/ATR
signaling pathway [3,6,23,35]. These kinases phosphorylate and
activate Chk1 and Chk2, which in turn phosphorylate and
inactivate Cdc25C phosphatase resulting in blocking the activation
of Cdk1 and transition into mitosis [36–39]. They also phosphor-
ylate p53 leading to its accumulation and activation resulting in
increased transcription of cell cycle arrest-related genes such as
p21CIP, GADD45, and 14-3-3d [40,41]. Moreover, Histone
H2A.X becomes locally phosphorylated by ATM/ATR at the
vicinity of DNA strand break to generate c-H2A.X, a well-known
marker for DNA strand break [42,43]. In agreement with c-
H2A.X signal (Fig. 3C), STK295900 also did not trigger DNA
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damage checkpoint pathway (Fig. 3B). Furthermore, STK295900
showed protective effect against DNA damage induced by
camptothecin but not by etoposide (Fig. 4C). Thus, STK295900
at physiological concentration may prevent the binding of Top 1
to DNA and, as a consequence, prevent Top 1 poison-induced
DNA damage. However, further study is needed to determine the
precise mechanism underlying the inhibitory activity of
STK295900 on Top 1 and Top 2.
Basically, G2 arrest is regulated through the control of Cdk1
activity, which is regulated at multiple levels. In addition to
association with cyclin B, the Cdk1 complex is activated by
phosphorylation at T161 by Cdk-activating kinase (CAK).
However, the cyclin B/Cdk1 complex is kept inactive by
Figure 4. STK295900 inhibits topoisomerases activities. Supercoiled DNA relaxation assay for (A) topoisomerase 1 (Top 1) and (B)
topoisomerase 2 (Top 2). Supercoiled pBR322 plasmid DNA was incubated at 37uC for 30 min with Top 1 enzyme (A) or Top 2a (B) in the presence of
various concentrations of indicated compounds. DNA samples were separated by electrophoresis on a 1% agarose gel, stained with ethidium
bromide, and visualized by UV light. (2), supercoiled DNA alone; oc, open circular; sc, supercoiled. (C) Antagonistic effect of STK295900 in
camptothecin-induced DNA damage. HeLa cells were pretreated with 10 mM of STK295900 for 30 min and then incubated with the indicated
concentrations of camptothecin for 1 h. Treated cells were lysed and subjected to immunoblot analyses with antibody against c-H2A.X. b-actin was
used as a loading control. (D) Antagonistic effect of STK295900 on etoposide-induced DNA damage. HeLa cells were pretreated with STK295900 at 10,
20, 30, or 50 mM or ICRF-193 at 10 mM for 30 min. Cells were incubated with 10 mM of etoposide for another 1 h. Treated cells were then lysed and
subjected to immunoblot analyses with antibody against c-H2A.X. b-actin was used as a loading control.
doi:10.1371/journal.pone.0053908.g004
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phosphorylation of Cdk1 at T14 and Y15 by Myt1 and Wee1,
respectively [20,44,45]. Therefore, the activity of Cdk1 is
regulated by the balance between the inhibitory kinases and the
activating Cdc25 phosphatases that remove phosphates from T14
and Y15 for a timely control of G2/M transition [46]. Fig. 3A
demonstrated that STK295900 induced G2 arrest was not
associated with Wee1- and Myt1-mediated inhibitory phosphor-
ylation of Cdk1 on T14 and Y15. However, further investigation is
required to fully elucidate the mechanism of G2 arrest induced by
STK295900.
Collectively, comparison of STK295900 with camptothecin,
etoposide, and Hoechst 33342 for their growth inhibitory effects
indicated that STK295900 is more cytotoxic to cancer cell lines
than to normal cell lines (Table 2). STK295900 and the other
symmetric bibenzimidazole derivatives are suggested to have
potentials to be developed as anticancer agents.
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